The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI
The FGFR family is involved in the early induction of reactive microglia in TBI. FGFR inhibition selectively prevented FGFR phosphorylation in the microglia, dampened the overall neuroimmunological response and enhanced the preservation of neuronal and synaptic integrity. Thus, FGFR inhibitors may be relevant targets for drug repurposing aimed at modulating microglial reactivity in TBI.
Authors
- Florian olde Heuvel (ORCID: https://orcid.org/0000-0002-1109-8969)
- Markus Huber‐Lang (ORCID: https://orcid.org/0000-0003-2359-6516)
- Francesco Roselli (ORCID: https://orcid.org/0000-0001-9935-6899)
- Albrecht Froehlich
- Tobias M. Boeckers (ORCID: https://orcid.org/0000-0002-1486-8535)
- Lobna Elsayed
- Maria Cristina Morganti-Kossmann (ORCID: https://orcid.org/0000-0002-0807-2063)
- Rida Rehman (ORCID: https://orcid.org/0000-0003-0518-5051)
Institutions
- Barrow Neurological Institute (US)
- University of Arizona (US)
- Universität Ulm (DE)
- German Center for Neurodegenerative Diseases (DE)
- Phoenix Children's Hospital (US)
- Stanford University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1443940
- Citations
- 3
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.74
Funders
- Deutsche Forschungsgemeinschaft